| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GTHX | Common Stock | Sale | -$6.67K | -2.72K | -0.62% | $2.45 | 434K | Jul 5, 2023 | Direct | F1, F2, F3 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. Such sales were automatic and intended to qualify under Rule 10b5-1. |
| F2 | The price represents the weighted average price with a low of $2.4250 and a high of $2.4704. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | Represents (i) 93,002 shares of common stock; (ii) 71,111 RSUs from award granted on January 1, 2021; (iii) 28,750 RSUs from award granted on January 3, 2022; (iv) 80,700 RSUs from award granted on January 3, 2023; and (v) 160,000 RSUs from award granted on May 10, 2023. |